http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NL-2020520-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_288cd8d9be9afaa99ee19773c5cfb464 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-248 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate | 2018-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcc7298bbe4e7a858609d961f61b1c8a |
| publicationDate | 2019-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NL-2020520-B1 |
| titleOfInvention | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| abstract | The invention relates to a multispecific binding molecule, preferably an antibody, comprising at least a first binding site binding to a first target selected from the group comprising human tau protein and post-translationally modified human tau protein, such as phosphorylated, acetylated, glycosylated, glycated, prolylisomerizated, nitrated, polyaminated, ubiquitinated, sumoylated, oxidated, aggregated, cleaved human tau protein and truncated versions thereof, (1- synuclein, TDP43, mHTT, and fragments thereof and at least a second binding site binding to a second target selected from the group comprising human tau protein and post-translationally modified human tau protein, such as phosphorylated, acetylated, glycosylated, glycated, prolyl-isomerizated, nitrated, polyaminated, ubiquitinated, sumoylated, oxidated and aggregated human tau protein and cleaved and truncated versions thereof, o-synuclein, TDP43, mHTT, Clq, C5a, ILlB, 1L6, TNF-o, APOE, IL12, IL23 and fragments thereof, Wherein the first and second target are different. Further, the invention relates to a method, a diagnostic method and use of the binding molecules, specifically antibodies of the invention for the treatment and prevention of neurodegenerative diseases. |
| priorityDate | 2018-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2373.